2022 World Conference on Lung Cancer (ePosters)-EP14.05-009. LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)

Pdf Summary

The poster presented at the IASLC 2022 World Conference on Lung Cancer introduces the LUMINANCE study (NCT04774380), which is funded by AstraZeneca. The study aims to evaluate the safety and efficacy of durvalumab in combination with platinum-etoposide chemotherapy as a first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC).<br /><br />The LUMINANCE study is a phase IIIb, open-label, single-arm, international, multicentre study. It will enroll 150 patients with previously untreated ES-SCLC, including those with a poor performance status. The patients will receive durvalumab intravenously concurrently with platinum-based chemotherapy (cisplatin or carboplatin) and etoposide every 3 weeks for 4-6 cycles, followed by durvalumab every 4 weeks until disease progression.<br /><br />ES-SCLC is an aggressive malignancy with a poor prognosis, and platinum-based chemotherapy has been the standard first-line treatment. However, the introduction of immune checkpoint inhibitors, including durvalumab, has shown significant improvements in survival outcomes. The CASPIAN study demonstrated a statistically significant improvement in overall survival with durvalumab plus chemotherapy compared to chemotherapy alone.<br /><br />The LUMINANCE study aims to collect safety and efficacy data in patients with ES-SCLC, including those with a poor performance status, and will help inform treatment decisions in real-world clinical practice. It will also explore potential biomarkers to identify patients who may benefit the most from durvalumab.<br /><br />The poster provides information on the study design, inclusion and exclusion criteria, study endpoints, and planned or active recruitment in various countries. The primary endpoint of the study is safety and tolerability, assessed by grade 3 adverse events and immune-mediated adverse events. Secondary endpoints include progression-free survival, overall response rate, duration of response, 12-month progression-free survival, 12-month duration of response, overall survival, and 12-month overall survival.<br /><br />The LUMINANCE study is currently active and recruiting patients, with primary completion expected in June 2023. The results of this study will contribute to our understanding of the efficacy and safety of durvalumab in combination with chemotherapy as a first-line treatment for patients with ES-SCLC.

Asset Subtitle

Niels Reinmuth

Meta Tag

Speaker Niels Reinmuth

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

IASLC 2022 World Conference on Lung Cancer

LUMINANCE study

NCT04774380

AstraZeneca

durvalumab

platinum-etoposide chemotherapy

extensive-stage small-cell lung cancer

ES-SCLC

phase IIIb study

immune checkpoint inhibitors